Hyaluronidase & Dissolving Filler 2026: Emergency Reversal Protocols for Med Spas

Every filler practice owns a small, unremarkable vial that almost never gets used — and that single vial is the difference between a frightening complication and a permanent injury followed by a lawsuit. Hyaluronidase is the enzyme that breaks down hyaluronic acid (HA) filler. In a med spa it does two very different jobs: in the routine case it dissolves filler a patient wants removed, and in the emergency case it is the antidote to vascular occlusion, the rare event in which filler cuts off the blood supply to skin or, at worst, to the eye. The first job is elective and unhurried. The second is a clock-driven emergency where the practice either acts within the window or watches tissue die.

This is a compliance and readiness guide, not an injection manual. We will not tell you how to thread a cannula or where to place a bolus — that is the clinical domain of your injectors and your medical director. What we will map is everything an operator is responsible for governing: why on-site hyaluronidase has become an expectation rather than a nicety, what the emergency reversal protocol must contain, how dosing and repeat-dosing work at a policy level, how elective dissolving differs and what its consent must say, the allergy and anaphylaxis questions, how to stock and store the drug, who may administer it under your state's rules, and the documentation that proves — to a board or a jury — that you were ready before anything went wrong. If you offer HA filler, this is the part of your risk surface that is easiest to fix and most expensive to ignore.

Why Hyaluronidase Is the Most Important Drug in a Filler Practice

Most of the medications a med spa keeps are conveniences. Hyaluronidase is not. It is the only agent that can reverse what filler does, and it is the only meaningful treatment for the one filler complication that is both catastrophic and time-sensitive. A practice can inject filler competently for years and never need it — and then need it desperately, once, with no time to acquire it. That asymmetry is exactly why it sits at the center of every defensible filler protocol.

The antidote nobody plans to use

Vascular occlusion is uncommon, and that rarity is its trap. Because injectors rarely see one, it is tempting to treat hyaluronidase as optional inventory — something to order if a patient ever asks to dissolve, not something to keep stocked for an event that may never come. But the entire logic of emergency readiness is built around low-probability, high-consequence events. You do not keep an AED because cardiac arrests are common in your lobby; you keep it because when one happens, nothing else will do and there is no time to go get one. Hyaluronidase is the filler equivalent. The supporting literature is blunt about this: a 2024 review in JMIR Dermatology on hyaluronidase applications and dosing describes it as the cornerstone of filler-complication management precisely because nothing else reverses an HA occlusion.

Why "available" is being redefined as "on site"

For years, "having access to hyaluronidase" was treated loosely — a vial somewhere in the building, or the ability to get some quickly. The standard has tightened. Commentary in the medical literature now frames on-site availability as a shared safety responsibility across everyone who injects HA filler; a 2025 discussion in the U.S. National Library of Medicine on hyaluronidase availability beyond the aesthetic office argues that the drug should be present wherever filler is placed, not merely reachable. The practical translation for an operator is that "we can get some" is no longer a defensible answer. The expectation is that it is in your building, in date, and in quantity, the moment the syringe comes out. This is the same standard-of-care logic our companion guide on dermal filler complications applies across the full complication spectrum.

Two jobs, one drug, two protocols

The single biggest conceptual mistake operators make is treating "dissolving filler" and "reversing an occlusion" as the same activity because they use the same drug. They are not. Elective dissolving is a scheduled, consented, unhurried procedure with time for screening and discussion. Emergency reversal is a reflexive, high-dose, repeated intervention executed against a clock. Your SOP library should treat them as two distinct protocols that happen to share a vial — different consent, different urgency, different dosing logic, and different documentation. Conflating them is how a practice ends up under-dosing an emergency or over-formalizing nothing at all.

Emergency Reversal: The Vascular-Occlusion Protocol

The emergency protocol is the reason hyaluronidase belongs in your building. It is the most legally sensitive sequence in aesthetic medicine, and it must be written, rehearsed, and reflexive — because the moment it is needed, there is no time to read, debate, or improvise.

Recognizing the occlusion that triggers it

The protocol begins with recognition, and recognition is a pattern, not a diagnosis. The classic signs that appear during or shortly after injection include disproportionate pain, immediate blanching (a white or pale patch where blood supply is cut off), and a dusky, mottled, or blotchy discoloration that follows the course of a vessel rather than sitting at the injection point. Delayed capillary refill, coolness, a net-like livedo pattern, and later blistering signal that an untreated occlusion is progressing. Any vision change, severe headache, or neurologic symptom points to a far more serious embolic event. The training rule baked into the SOP is unambiguous: at the first suspicion, stop injecting and activate the protocol — do not wait to see whether it improves. Our dedicated vascular occlusion guide covers recognition in clinical depth and pairs directly with this readiness protocol.

The reflexive response sequence

A protocol is only useful if it specifies the order of operations before anyone is under stress. At a policy level, the occlusion sequence is: stop the injection immediately; begin the hyaluronidase protocol under medical direction; apply supportive measures per your medical director's protocol; notify the medical director; and define the explicit threshold at which the patient is escalated to an emergency department or specialist. Any sign of visual or neurologic involvement bypasses the rest and escalates to emergency care at once. The value of writing this down is that it removes decisions from the moment of panic — the staff are executing a rehearsed sequence, not inventing one.

Where hyaluronidase fits — and the clock that governs it

Hyaluronidase is the center of the sequence, and timing is everything. The reperfusion window is measured in hours, not days: published management literature and case series consistently report that earlier administration yields better tissue survival, with the best outcomes when treatment begins within the first few hours and meaningful benefit still possible within roughly a day. That single fact drives the entire stocking and readiness argument — a drug that must be given within hours is worthless if it has to be ordered, retrieved, or located during the emergency. The protocol therefore assumes the drug is already in the room, the dosing is already decided, and the authorized administrator is already on site.

Dosing and Repeat-Dosing in an Emergency

Operators do not set dosing — physicians do — but operators are responsible for ensuring a dosing protocol exists, is signed, and is stocked to support. Understanding the shape of emergency dosing is what makes the stocking and supervision requirements make sense.

High-dose, flooding, and the angiosome approach

Emergency occlusion dosing bears little resemblance to the small amounts used for elective touch-ups. The published approach is high-dose and aims to flood the ischemic territory so the enzyme saturates and penetrates the occluded vessel. Modern protocols describe dosing keyed to the affected angiosome (the territory a given artery supplies) with substantial unit counts per treatment area. A widely referenced framework — the modified high-dose pulsed approach detailed in the peer-reviewed guideline for the safe use of hyaluronidase in aesthetic medicine — describes repeated high-dose administration rather than a single injection. The numbers vary across protocols, which is exactly why your practice must adopt one specific protocol rather than leaving providers to recall figures under pressure.

Repeat dosing until reperfusion

The feature that most often catches under-prepared practices off guard is that emergency hyaluronidase is not one-and-done. Protocols typically call for re-assessing perfusion and repeating administration at intervals — for example, reassessing every period defined by your protocol — until capillary refill, color, and pain indicate blood flow has returned. A single occlusion can therefore consume far more of the drug than the entire rest of the year's elective dissolving combined. A practice that owns one small vial has, in effect, owned enough for the first few minutes of an event that may run for hours.

Why your medical director must sign the dosing protocol

Because published dosing still varies between sources and much of this use remains off-label, the unit counts and intervals are not something an operator should pull from a blog or a forum. The compliance requirement is that your medical director adopts a specific, written dosing protocol and signs it, with a clear reference for the units per area and the repeat interval, so that in the emergency the team executes a pre-authorized standard rather than improvising. That signed protocol is also what proves, after the fact, that the dosing used was the practice's adopted standard of care — not a number someone guessed at in the moment.

Elective Dissolving: Indications and Consent

The everyday use of hyaluronidase is elective dissolving — removing or adjusting HA filler a patient is unhappy with. It is far lower-stakes than an occlusion, but it carries its own consent and expectation-management obligations that an SOP must address, because dissatisfaction after dissolving is a common source of disputes.

When patients ask to dissolve

Patients request dissolving for predictable reasons: overcorrection or an unnatural result, migration of product away from the intended area, palpable lumps or asymmetry, the Tyndall effect (a bluish discoloration from superficial placement), or simply wanting to start over before being re-treated. Some arrive having had filler placed elsewhere and may not know what product was used or how much — a meaningful gap, since hyaluronidase only works on HA. The intake for an elective dissolving must therefore establish, as far as possible, what was placed, where, when, and how much, and document the patient's actual complaint and goal.

Setting realistic expectations — including over-dissolving native HA

The expectation patients least anticipate is that dissolving is not perfectly precise. Hyaluronidase can also affect the body's native hyaluronic acid in the treated area, which can transiently leave the area looking flatter, more deflated, or older than before the filler was placed, until the tissue recovers. Results can also be uneven, and more than one session may be required. A patient who expects to walk out looking exactly as they did before any filler — instantly and precisely — is set up for disappointment. The SOP should require that these realities are discussed and consented to, not discovered afterward.

A dissolving-specific consent

Dissolving deserves its own consent rather than a line buried in the filler form. It should disclose that only HA filler can be dissolved; that the result may be incomplete, uneven, or require repeat sessions; that native HA may be affected with a temporary loss of volume; that there is a rare risk of allergic reaction to hyaluronidase itself; and that re-treatment, if desired, must wait an appropriate interval. This mirrors the broader consent discipline covered in our guide to Botox and injectable consent forms — named, specific risks, acknowledged before treatment, beat generic boilerplate every time.

Allergy, Patch Testing, and Anaphylaxis Readiness

Hyaluronidase is generally well tolerated, but it is a protein-based product and can provoke hypersensitivity. The compliance question is not whether reactions are common — they are rare — but whether your protocol handles them differently in the elective versus emergency setting, and whether you are equipped if one occurs.

The bee and wasp sting cross-reactivity question

A recurring screening point in the literature is a history of significant reactions to bee or wasp stings, because of possible cross-reactivity with hyaluronidase. For elective, non-urgent dissolving, guidance suggests caution in these patients and, where a history of a large local reaction or anaphylaxis to stings exists, consideration of intradermal testing by an allergist before proceeding. This is a question your intake should ask and your protocol should address — not a detail to discover after the injection.

The patch-test debate

Whether to patch test before hyaluronidase is genuinely debated, and the answer depends on context. In a true occlusion emergency, treatment is not delayed for testing — the danger of withholding the antidote far outweighs the rare risk of a reaction, and the protocol proceeds with anaphylaxis readiness on hand. For elective dissolving, a more cautious posture is reasonable, particularly in higher-risk patients. The point for an operator is that this is a clinical judgment that belongs to your medical director and must be written into the protocol as a decision rule, so providers are not improvising the test-or-not question case by case.

Anaphylaxis readiness alongside hyaluronidase

Wherever hyaluronidase is administered, the means to manage a reaction must be present. The literature recommends having antihistamines and injectable hydrocortisone available, and a practice must also have epinephrine and an anaphylaxis protocol ready as a baseline. In other words, you cannot separate hyaluronidase readiness from emergency readiness generally — they are the same kit and the same training. Our anaphylaxis protocol for med spas guide covers the recognition and response standard that must sit alongside every hyaluronidase administration.

Stocking, Storage, and Expiry Management

Owning hyaluronidase and being stocked for an emergency are different things. This is the section where good intentions most often fall apart in an inspection or a deposition — the vial exists, but it is expired, single, or stored wrong.

How much to keep on hand

There is no universal number, but the logic is fixed: stock enough to manage a vascular occlusion under the high-dose, repeated protocol you have adopted, not enough for a casual touch-up. Because an occlusion can require large cumulative doses over hours, a token supply is a liability. Your medical director should set a minimum stock level keyed to the adopted dosing protocol and the largest plausible occlusion, and that minimum should be documented so anyone can verify the shelf meets it at a glance.

Storage and reconstitution

Hyaluronidase has specific storage requirements that vary by formulation, and some forms require reconstitution before use. Your SOP should record the storage conditions for the product you stock (temperature and handling), whether and how it is reconstituted, and the stability window once prepared. Storing it incorrectly can quietly render your supply ineffective — a failure that would only be discovered at the worst possible moment. Storage details should live in the same SOP as the dosing protocol so the two are never out of sync.

Expiry tracking and restock triggers

The most common readiness failure is an expired vial discovered during an emergency. The fix is mundane and non-negotiable: a documented expiration-tracking process and a restock trigger. Every vial's expiration date should be logged; a recurring check (monthly is typical) should flag anything approaching expiry; and a restock trigger should ensure replacement before the supply is depleted or out of date. The log itself is dual-purpose — it keeps the shelf ready and it documents, after the fact, that readiness was actively maintained rather than assumed.

Who May Administer Hyaluronidase Under Supervision

Hyaluronidase is a prescription drug, so the question of who may give it is governed by state law and medical direction — not by the product or by convenience. Getting the authorization structure right is what makes emergency administration legally possible in the first place.

Standing orders and medical direction

Because it requires a prescriber's authorization, hyaluronidase use must be backed by a physician through a standing order or protocol, and administered by a provider acting within their licensed scope — typically a physician, nurse practitioner, physician assistant, or registered nurse, depending on the state. The standing order is the legal mechanism that lets a nurse administer the drug in an emergency without obtaining a fresh order each time — which only works if that order is already signed and on file before the emergency. An unsigned or absent standing order means the very people most likely to be in the room cannot legally act. The scope-of-practice principles here echo those in our guide on who can inject Botox across the United States.

Emergency administration versus elective dissolving

The authorization for the two uses can differ. Emergency administration during an occlusion is governed by the standing order and the occlusion protocol; elective dissolving may carry additional good-faith-exam, supervision, and consent requirements depending on your state. Your protocol should make the distinction explicit and document, for every staff member who may administer the drug, the authorization that covers them and the supervision level required. "Anyone who injects can give it" is not an authorization structure — it is the absence of one.

Building the Emergency Kit and Readiness Checklist

Hyaluronidase does not sit alone. It is one component of a filler emergency kit, and readiness means the whole kit is present, current, and rehearsed — not just that the antidote is in a drawer somewhere.

What belongs in the filler emergency kit

A defensible filler emergency kit, assembled around your medical director's protocols, typically includes:

• Hyaluronidase in the quantity your high-dose occlusion protocol requires, with current expiration dates
• Supplies for administration and supportive measures as specified in your occlusion SOP
• Anaphylaxis management — epinephrine, antihistamines, and injectable hydrocortisone, with the anaphylaxis protocol posted
• The written vascular-occlusion protocol and dosing reference, physically accessible at the point of care
• The standing order authorizing administration, on file and current
• Emergency contact and escalation information — medical director, nearest emergency department, and ophthalmology referral pathway

Drills and staff readiness

A kit nobody has practiced with is a prop. The readiness standard a board or insurer respects includes periodic drills — staff walking through the occlusion sequence, locating the kit, confirming dosing references, and rehearsing the escalation calls. These drills should be documented with dates and attendees, because the documentation is what later proves the team was trained, not merely equipped. A practice that can show a logged drill schedule is in a far stronger position than one whose first run-through of the protocol is the real emergency.

Documentation That Proves Standard-of-Care Readiness

Readiness that cannot be proven is, for legal purposes, readiness that did not exist. The records below are what convert "we were prepared" from an assertion into evidence — and they have to exist before any incident.

The readiness file

Assemble a standing readiness file that an inspector, insurer, or attorney could be handed on request. It should contain the physician-signed vascular-occlusion and hyaluronidase protocol (including the adopted dosing and repeat interval), the standing order naming authorized administrators, the emergency-kit inventory with current expiration dates, the restock and expiry log, the drill and training records, and the consent templates, including the separate dissolving consent. Each clinical document should carry a version date and a medical director signature date. This is the same documentation discipline that underpins our guide on the med spa emergency protocol and lawsuit exposure.

The incident record when it is used

If the protocol is ever executed, the contemporaneous record is decisive. It should capture what was recognized and when, the time of each hyaluronidase dose and the units given, the reassessment findings, who was notified, the escalation decisions and times, and the follow-up plan with serial photographs. A record created the same day carries far more weight than one reconstructed after a complaint arrives. As the American Med Spa Association consistently emphasizes in its coverage of med spa compliance and adverse-event readiness, the existence of a written protocol and a record that it was followed is repeatedly the dividing line between a defensible event and an indefensible one.

How it reads to a board or a jury

Put together, these records tell a single story: a written standard existed before the incident, the practice was equipped to meet it, the staff were trained to execute it, and when the moment came they did. That narrative reframes a bad outcome from "an unprepared practice that got unlucky" into "a prepared practice that anticipated this exact scenario and ran its protocol." Specialty guidance such as the ASDS guideline on preventing and treating filler complications is a useful reference point when your medical director defines exactly what your readiness file should contain.

Common Hyaluronidase Mistakes

Most readiness failures are not exotic. They are the same handful of predictable gaps, each of which is cheap to close in advance and ruinous to discover during an emergency or in discovery.

The recurring failures

• Treating "we can get some" as readiness. An antidote that must be given within hours is useless if it is not already in the room.
• Stocking a single small vial. A high-dose, repeated occlusion protocol can exhaust a token supply in minutes.
• Letting it expire. An expired vial discovered mid-emergency is the clearest possible breach of the standard of care.
• No signed dosing protocol. Improvised dosing under pressure is both clinically risky and legally indefensible.
• No standing order. Without it, the nurse most likely to be present cannot legally administer the drug.
• Confusing dissolving with reversal. Treating an emergency with elective-sized doses, or skipping consent on elective dissolving, are two sides of the same conflation.
• Assuming it works on every filler. Hyaluronidase does nothing for biostimulatory or permanent fillers — which is why the product placed must be documented.
• Never drilling. A protocol no one has rehearsed is discovered, for the first time, during the worst moment to read it.

Every item on that list is a documentation or stocking decision, not a clinical-skill question — which means every one of them is squarely within an operator's control to fix before the next syringe is opened.